NCT05105425已完成不适用
The Effects of Daily Supplementation of Nutriose® on the Fecal Microbiota in Volunteers Over 4 Weeks: a Randomized, Double-blinded, Placebo Conrolled Pilot Study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 124
- 试验地点
- 4
- 主要终点
- Comparison at V3 of relative abundance of Parabacteroides genus in intestinal microbiota
研究概览
简要总结
The effects of daily supplementation of the NUTRIOSE® on the fecal microbiota. The hypothesis of the study is that the NUTRIOSE® is able to modulate the intestinal microbiota in a positive way, compare to a placebo, in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
A RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED PILOT STUDY
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male volunteer,
- •Age between 18 and 60 years (limits included),
- •BMI between 18.5 and 25 kg/m² (limits included),
- •Having a high or a low usual fiber consumption,
- •With a usual normal intestinal transit. According to stool questionnaire completed between V1 and V2, mean of the 7 days of completion, maximum 3 stools / day and 5 stools/weeks minimum and with mean normal consistency (from type 3 to type 5 of the BSFS and with a tolerance of 1 to 3 stools in deviation /week) according to the investigator's opinion,
- •Non-smoking or with tobacco consumption < 5 cigarettes / day and agreeing to keep his smoking habits unchanged during the all duration of the study,
- •Weight stable within ± 5% in the last three months;
- •No significant change in food habits or in physical activity in the 3 months before the study and agreeing to keep these habits unchanged throughout the study;
- •Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination,
- •Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,
- •Affiliated with a social security scheme
- •Agreeing to be registered on the national file of volunteers in biomedical research file.
排除标准
- •Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder,
- •Suffering from gastrointestinal disorders such as celiac disease, Crohn's disease, functional constipation, irritable bowel syndrome or another gastrointestinal found to be inconsistent with the study according to the investigator,
- •Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, uncontrolled cardiac disease, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or another severe disorders found to be inconsistent with the conduct of the study by the investigator,
- •With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient,
- •Lactose intolerant,
- •Having undergone recent surgical procedure in the past 6 months or planned in the 2 months to come,
- •Under treatment which could significantly affect parameter(s) followed during the study according to the investigator or stopped less than 4 weeks before the V1 visit, i.e. medication with impact on intestinal transit such as anti-diarrheal, anti-spasmodic, antidepressants antibiotics, antacids, laxative, antifungal, NSAI, antivomiting, corticoids, opioids, narcotic analgesic and biliary acids chelator, and chronic hormonal treatment started less than 3 months ago (i.e. new method of hormonal contraception, thyroidal trouble treatment)
- •Regular intake of dietary supplements or "health foods", or products known to impact intestinal microbiota, containing or rich in prebiotic, probiotic, synbiotics, fiber, fermented milk or yogurt, kefir, ultra-yeast, vitamins and minerals or stopped less than 3 months before the inclusion visit (V1);
- •With a current or planned in the next 3 months specific diet (hyper or hypocaloric, vegan, vegetarian...) or stopped less than 3 months before the study,
- •With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,
- •Consuming more than 3 standard drinks of alcoholic beverage or not agreeing to keep his alcohol consumption habits unchanged throughout the study,
- •Having a lifestyle deemed incompatible with the study according to the investigator including high level physical activity (defined as more than 10 hours of significant physical activity a week, walking excluded),
- •Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
- •Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros,
- •Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
- •Presenting a psychological or linguistic incapability to sign the informed consent,
- •Impossible to contact in case of emergency.
结局指标
主要结局
Comparison at V3 of relative abundance of Parabacteroides genus in intestinal microbiota
时间窗: 4 weeks
Assessed via Shotgun metagenomics analysis
次要结局
- Comparisons at V3 and V4 of intestinal parameters: Secretory immunoglobulin A in feces(2 weeks)
- Comparisons at V3 and V4 of relative abundance of intestinal microbiota (Bacterial species of Parabacteroides genus, Bacteroides genus, Firmicutes phylum, the functional levels of the intestinal microbiota, ...)(2 weeks)
- Comparisons at V3 and V4 of intestinal parameters: Fecal short chain fatty acids (SCFA)(2 weeks)
- Comparison at V4 of relative abundance of Parabacteroides genus in intestinal microbiota.(7 or 8 weeks)
- Comparisons at V3 and V4 of intestinal parameters : Fecal pH(2 weeks)
- The frequency of adverse events(7 or 8 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
尚未招募
不适用
The effect of daily consumption of a probiotic drink containing Lactobacillus casei Shirota on the small intestinal microbiota in healthy male subjects as measured by the Intellicap sampling capsule system.<br>Effect of probiotics on small intestinal microbiotaSmall intestinal microbiotaNL-OMON45590The Yakult Honsha European Research Center for Microbiology, ESV (YHER)6
招募中
不适用
Effect of Probiotic Supplementation on Fecal Microbiota, Nutritional Status, Metabolic and Inflammatory Parameters in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT05418179Universidade Federal de Santa Catarina80
已完成
不适用
Metabolic Effects of Lactobacillus Reuteri DSM 17938 in Type 2 DiabetesType 2 DiabetesNCT01836796Vastra Gotaland Region46
尚未招募
3 期
Effects of synbiotic supplementation on intestinal microbiota , antioxidant status and short chain fatty acids among pediatric obesity : A Randomized clinical trialThe modulation of gut microbiota, metabolites, and short-chain fatty acids in obese Thai children while receiving synbiotics.obesity, synbiotic, prebiotic, probiotic, short chain fatty acids, metabolites, gut microbiotaTCTR20240321005Faculty of Medicine, Chulalongkorn University60
已完成
不适用
The Impact of Probiotics on Well-being in WomenFemaleHealthy AgingNCT06507111Cultech Ltd50